This is a prospective study of 35 patients. The daily dosages were 2-20 mg of haloperidol and 2-8 mg of risperidonum. The scoring is according to Positive and Negative Symptoms Assessment Scoring Scale (PANSS) and to Liverpul's University Neuroleptics Side Effects Rating Scale (LUNSERS). The patients were treated in hospital and ambulatory. The patients included in the study are diagnosed with schizophrenia according the DSM- IV criteria. 23 of them are male and 12 are female, from 18-50 years old. The preliminary result of PANSS for is more than 60 points. Pregnant women or those during lactation, drug and alcohol users, patients with organic comorbidity, and those treated previously with atypical antipsychotic medications, were not included in the study.

Both medicaments are effective on improving the symptoms of schizophrenia, but a superiority of risperidonum on improving positive and negative symptoms of this syndrome, is noticed. Risperidonum is safer, since it causes less side effects (with the value of p=0.106 not statistically important) in comparison with haloperidol which causes more side effects, (with the value of p=0.001 statistically important).